ReviewTargeted oncology2025

Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review.

David B Miklos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.